Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma

BMC Veterinary Research
Abbey R SadowskiC London

Abstract

Chemotherapeutic options for the treatment of canine lymphoma have not changed in several decades necessitating the identification of new therapeutics to improve patient outcome. KPT-335 (verdinexor) is a novel orally bioavailable selective inhibitor of nuclear export (SINE) that exhibited anti-tumor activity against non-Hodgkin lymphoma in a prior phase I study. The objective of this phase II study was to expand upon the initial findings and assess the activity and safety in a larger population of dogs with lymphoma. Fifty-eight dogs with naïve or progressive B-cell and T-cell lymphoma were enrolled in this clinical trial. KPT-335 was administered orally in one of three dosing groups, based on the previously established biologically active dose of 1.5 mg/kg three times weekly. Treatment with single-agent, orally administered KPT-335 resulted in an objective response rate (ORR) of 37%, of which dogs with T-cell lymphoma had an ORR of 71%. KPT-335 was well tolerated in all dose groups with grade 1-2 anorexia being the most common adverse event. Anorexia was responsive to symptomatic and supportive medications, including prednisone. These data demonstrate that KPT-335 has biologic activity in canine lymphoma, and support continue...Continue Reading

References

Jul 11, 2003·The Veterinary Clinics of North America. Small Animal Practice·Timothy M Fan
Mar 17, 2010·Veterinary and Comparative Oncology·D M VailUNKNOWN Veterinary Cooperative Oncology Group
Jan 3, 2012·Biochemical Pharmacology·Joel G TurnerDaniel M Sullivan
Jun 9, 2012·Blood·Parvathi RanganathanRamiro Garzon
Oct 16, 2014·Journal of Hematology & Oncology·Kaushal ParikhDelong Liu
Dec 6, 2014·Journal of Hematology & Oncology·Giovanni Luca GravinaClaudio Festuccia
Mar 2, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albiruni R Abdul RazakAmit Mahipal
Aug 11, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas B AlexanderJeffrey E Rubnitz
Sep 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ying ChenJohn A Martignetti

❮ Previous
Next ❯

Citations

Nov 25, 2018·Cells·Friederike K Kosyna, Reinhard Depping
Jul 28, 2020·International Journal of Molecular Sciences·Venkataramanan RamadassVinay Tergaonkar
Sep 17, 2020·Nature Reviews. Cancer·Amy K LeBlanc, Christina N Mazcko
Nov 12, 2020·Nature Reviews. Clinical Oncology·Asfar S AzmiRamzi M Mohammad
Jan 14, 2021·Veterinary and Comparative Oncology·Justin T BreitbachJoelle M Fenger
Aug 14, 2021·Journal of Experimental & Clinical Cancer Research : CR·Lijia PanZhixiang Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autophagy & Aging: Inhibitors

The feed focuses on the role of nuclear export inhibitors and their effect on autophagy and the aging process.

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.